Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 (Q64378722)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

4

Ingo B Runnebaum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

8

Beth Karlan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

Richard E Buller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Mark S Shahin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Jo Ann Horowitz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Vikas Mahavni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Stan Petrauskas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Rolf Kreienberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Dennis Slamon

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Mark Pegram

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

567-572

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700473

10 November 2019

exact match

0 references

cites work

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Brain metastases in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Field cancerization: why late "recurrent" ovarian cancer is not recurrent.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700473

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12082456%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference